Suppr超能文献

糖皮质激素在治疗和预防过敏反应中的应用。

Glucocorticosteroids for the treatment and prevention of anaphylaxis.

机构信息

Primary Care Research & Development, Centre for Population Health Sciences, University of Edinburgh, UK.

出版信息

Curr Opin Allergy Clin Immunol. 2013 Jun;13(3):263-7. doi: 10.1097/ACI.0b013e32836097f4.

Abstract

PURPOSE OF REVIEW

To review recent evidence on the effectiveness of glucocorticosteroids in the treatment and prevention of anaphylaxis.

RECENT FINDINGS

Glucocorticosteroids are often used in the management of anaphylaxis in an attempt to reduce the severity of the acute reaction and decrease the risk of biphasic/protracted reactions. A recent Cochrane systematic review failed to identify any randomized controlled or quasi-randomized trials investigating the effectiveness of glucocorticosteroids in the emergency management of anaphylaxis. In contrast, randomized controlled trials have been undertaken of glucocorticosteroids, given individually or in combination with other drugs, in preventing anaphylaxis. Systematic reviews of these prophylactic approaches undertaken in patients being investigated with iodinated contrast media and treated with snake anti-venom therapy have found routine prophylaxis to be of questionable value. Trials of a combination of glucocorticosteroids and H1/H2-antihistamine premedication for preventing allergen immunotherapy-triggered anaphylaxis have yielded mixed results.

SUMMARY

Glucocorticosteroids should be regarded, at best, as a second-line agent in the emergency management of anaphylaxis, and administration of epinephrine should therefore not be delayed whilst glucocorticosteroids are drawn up and administered. Routine premedication with glucocorticosteroids in patients receiving iodinated contrast media, snake anti-venom therapy or allergen immunotherapy is unlikely to confer clinical benefit.

摘要

目的综述

回顾糖皮质激素治疗和预防过敏反应的最新证据。

最近的发现

糖皮质激素常用于过敏反应的治疗,试图减轻急性反应的严重程度,降低双相/迁延性反应的风险。最近的 Cochrane 系统评价未能确定任何随机对照或半随机试验研究糖皮质激素在过敏反应急救管理中的有效性。相比之下,已经进行了随机对照试验,研究了糖皮质激素单独或与其他药物联合用于预防过敏反应。对在接受碘造影剂检查和蛇毒治疗的患者中进行的这些预防方法的系统评价发现,常规预防的价值值得怀疑。糖皮质激素和 H1/H2 抗组胺药预用药联合预防过敏原免疫治疗引发的过敏反应的试验结果喜忧参半。

总结

糖皮质激素在过敏反应的急救管理中充其量只能被视为二线药物,因此在给予肾上腺素的同时不应延迟糖皮质激素的使用。在接受碘造影剂、蛇毒治疗或过敏原免疫治疗的患者中常规进行糖皮质激素预用药不太可能带来临床获益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验